May 31, 2016
Recommended Topic Related To:

Methyldopate Hcl

"The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the marketing of selexipag (Uptravi, Actelion Registration Ltd) for the treatment of adults with pulmonary arterial hypertension (PAH)./"...


Methyldopate Hcl



Acute overdosage may produce acute hypotension with other responses attributable to brain and gastrointestinal malfunction (excessive sedation, weakness, bradycardia, dizziness, lightheadedness, constipation, distention, flatus, diarrhea, nausea, vomiting).

In the event of overdosage, symptomatic and supportive measures should be employed. Management includes special attention to cardiac rate and output, blood volume, electrolyte balance, paralytic ileus, urinary function and cerebral activity.

Sympathomimetic drugs [e.g., levarterenol, epinephrine, ARAMINE* (Metaraminol Bitartrate, MSD)] may be indicated.

The acute intravenous LD50 of Methyldopate HCl (methyldopate hydrochloride injection, solution) in the mouse is 321 mg/kg.


Methyldopate hydrochloride is contraindicated in patients:

-with active hepatic disease, such as acute hepatitis and active cirrhosis.
-with liver disorders previously associated with methyldopa therapy (see WARNINGS).
-with hypersensitivity to any component of this product, including sulfites (see WARNINGS).
-on therapy with monoamine oxidase (MAO) inhibitors.

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 8/11/2008


Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Get tips on handling your hypertension.